Tempus

Climb for a Cure Raises $1 Million to Support High-Impact Colorectal Cancer Research

Retrieved on: 
Wednesday, September 6, 2023
Survivor, Ganser, CRC, Hope, Intelligence, Cure, Human, Research, Exact sciences, Helmy Eltoukhy, Tempus, Colorectal cancer, Medicine, Merck, System, Combat, Caregiver, Disease, Tourism, Pharmaceutical industry, Natera

Springfield, Mo., Sept. 06, 2023 (GLOBE NEWSWIRE) -- In an inspiring display of unity, determination, and community support, Fight Colorectal Cancer’s Climb for a Cure event has achieved a remarkable milestone by raising $1 million to advance colorectal cancer (CRC) research.

Key Points: 
  • Springfield, Mo., Sept. 06, 2023 (GLOBE NEWSWIRE) -- In an inspiring display of unity, determination, and community support, Fight Colorectal Cancer’s Climb for a Cure event has achieved a remarkable milestone by raising $1 million to advance colorectal cancer (CRC) research.
  • Since 2016, Climb for a Cure has been embraced by colorectal cancer survivors, caregivers, and dedicated loved ones who’ve engaged in physical challenges and fundraised to support finding a cure.
  • All dollars raised by this event go toward funding high-impact colorectal cancer research.
  • The funds raised through Climb for a Cure will be channeled into groundbreaking research endeavors to drive innovation and accelerate progress in CRC research.

Cadence Collaborates with Arm to Accelerate Neoverse V2 Data Center Design Success with Cadence AI-driven Flows

Retrieved on: 
Wednesday, August 30, 2023
Data Management, Technology, Security, Apps, Applications, Software, Artificial Intelligence, Networks, Internet, Mobile, Wireless, Hardware, Electronic Design Automation, Cadence Design Systems, RTL, CDNS, Arm, EDA, Palladium, Business, ML, M120 Rak, Central processing unit, ARM Neoverse, SOC, Protium, SBSA, PCI, Tempus, HPC, GDS, AI, Silicon, Digital, PPA, Environment, VIP, Video game, Cryptocurrency, Cadence, Helium

Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced an expanded collaboration with Arm to speed data center silicon success on the Arm® Neoverse™ V2 platform.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced an expanded collaboration with Arm to speed data center silicon success on the Arm® Neoverse™ V2 platform.
  • In addition, the Cadence® AI-driven verification full flow supports Neoverse V2, providing designers with optimal verification throughput and preparedness for Arm SystemReady compliance.
  • The digital RAKs provide Arm Neoverse V2 designers with several key benefits.
  • For example, the Cadence Cerebrus AI capabilities automate and scale digital chip design, delivering better PPA and improving designer productivity.

From HITECH to the COVID-19 PHE: These Real-World Data Technologies are Helping Define Evidence-Based Care

Retrieved on: 
Wednesday, August 30, 2023
Real-World Evidence, Cosmos, Komodo, Real, Research report, Drug development, Procurement, Thermo Fisher Scientific, Real world evidence, COVID-19, RWD, Electronic health record, Health policy, Organization, Evidence, Aetion, Acquisition, RWE, Health Information Technology for Economic and Clinical Health Act, Carev Dvor, Ecosystem, Public health surveillance, Health information management, Pharmaceutical industry, IQVIA, Tempus, Research

'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.

Key Points: 
  • 'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.
  • However, nearly 80% of healthcare data is still in unstructured formats, necessitating specialized solutions that can help process this data so it can be applied effectively.
  • "By working together, they can overcome barriers such as data fragmentation, data quality concerns, and regulatory uncertainties.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.

CureMD Announces Strategic Collaboration with Tempus to Integrate Genomic Testing Functionality in EHR

Retrieved on: 
Tuesday, August 22, 2023
Seattle Cancer Care Alliance, Survival, Electronic health record, Partnership, Intelligence, Health, Tempus, Prognosis, Patient, EHR, Physician, Risk, Medicine, Medical imaging

NEW YORK, Aug. 22, 2023 /PRNewswire/ -- CureMD, a leading provider of comprehensive technology solutions for community oncology, is proud to announce its partnership with Tempus, a leader in artificial intelligence and precision medicine, to integrate Tempus' advanced genomic testing capabilities into CureMD's cutting-edge Electronic Health Record (EHR) system.

Key Points: 
  • NEW YORK, Aug. 22, 2023 /PRNewswire/ -- CureMD, a leading provider of comprehensive technology solutions for community oncology, is proud to announce its partnership with Tempus, a leader in artificial intelligence and precision medicine, to integrate Tempus' advanced genomic testing capabilities into CureMD's cutting-edge Electronic Health Record (EHR) system.
  • "We are excited to join forces with Tempus to integrate their genomic testing capabilities into our EHR system," said Wasif Toor, VP of Oncology, CureMD.
  • The integration of Tempus' genomic testing into CureMD's ecosystem will empower healthcare providers to place genomic testing orders directly in the EHR at the point of care, allowing physicians to streamline their workflows and provide more genomic testing opportunities for patients.
  • The evolving collaboration will make discrete, structured genomic testing results available at the point of care in the EHR for timely treatment decisions, prognosis, and risk.

FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

Retrieved on: 
Tuesday, August 15, 2023
Technology, Medical Devices, FDA, Health Technology, Other Health, Biotechnology, General Health, Health, Oncology, Artificial Intelligence, LOH, Diagnosis, Cancer, CDX, Intelligence, Safety, Patient, HLA, Biomarker, Doctor of Philosophy, Medicine, Medical imaging, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.
  • The test uses a machine learning model to analyze sequence data produced by Tempus’ FDA-approved, next generation sequencing-based xT CDx assay.
  • “HLA-LOH provides a clear molecular distinction between cancer and non-cancer cells and is a potential biomarker for immune therapy resistance.
  • “This Breakthrough Device Designation from the FDA recognizes the novelty and potential clinical impact of our HLA-LOH test for this promising biomarker.

Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight

Retrieved on: 
Friday, July 14, 2023
Diversified Pharmaceutical Services, Abstract, Readout, AI, Biostatistics, General partnership, Statistics, Doctor of Philosophy, Cryptocurrency, Medical device, Tempus

Readout AI closes its pre-seed financing to further its development of AI for clinical trial analysis.

Key Points: 
  • Readout AI closes its pre-seed financing to further its development of AI for clinical trial analysis.
  • "We are beyond excited to have secured this funding from such impactful and supportive investors," said Matthew Michelson, PhD, CEO of Readout AI.
  • The goal is to alleviate the bottlenecks associated with clinical data analysis and reporting by turning trial data into accessible, human-readable insights, in seconds.
  • But Readout's AI can also help analyze and report on progression, which is a novel improvement," says Michael Shleifer, PhD, co-founder of Readout AI.

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

Retrieved on: 
Wednesday, July 12, 2023
Software, Research, Managed Care, Radiology, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Health, DNA, Circulating tumor DNA, Liquid biopsy, Intelligence, NSCLC, Doctor of Philosophy, AstraZeneca, MRD, HIV disease progression rates, Patient, XT, Medicine, XF, Neoplasm, TIME, GEMINI, Non-small-cell lung cancer, Pharmaceutical industry, Tempus

Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study ( NCT05236114 ).

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study ( NCT05236114 ).
  • The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset for patients with NSCLC to facilitate future novel research related to precision medicine, diagnostic development, and biomarker discovery.
  • The results of this study will be used for biomarker discovery, including potential use of circulating tumor DNA (ctDNA) testing to measure MRD.
  • “The GEMINI study addresses research gaps in a high-need patient population that the Tempus platform is uniquely positioned to undertake,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus.

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

Retrieved on: 
Thursday, July 6, 2023
Technology, Genetics, Other Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Artificial Intelligence, HLA, Neoplasm, Cancer, Intelligence, Head, Lung cancer, TCR, XT, Cervical cancer, Patient, Melanoma, Medicine, CDX, Ovarian cancer, Gene, Vaccine, Medical imaging, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients.
  • The collaboration supports TScan’s screening protocol for its Phase 1 solid tumor clinical trial which is designed to enable customized mixtures of TCR-Ts to be administered to patients based on tumor antigen positivity and intact HLA expression.
  • TScan plans to enroll patients with solid tumors including non-small cell lung cancer, melanoma, head and neck cancer, ovarian cancer, and cervical cancer.
  • TScan is collaborating with Tempus to use the xT assay, Tempus’ 648-gene panel, to prospectively identify patients with HLA loss in the tumor to select TCR-Ts that recognize HLA genes still intact in the patient’s tumor.

Cadence Delivers Certified, Innovative Backside Implementation Flow to Support Samsung Foundry SF2 Technology

Retrieved on: 
Wednesday, June 28, 2023
Semiconductor, Electronic Design Automation, Technology, Artificial Intelligence, Software, Cadence Design Systems, Samsung Electronics, RTL, CDNS, SF2, Samsung, Proposed UK Internet age verification system, Tempus, PDK, Foundry, Digital, Silicon, AI, PPA, Mobile phone, Cadence

Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced that it has delivered a complete, certified backside implementation flow to support Samsung Foundry’s SF2 process node.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced that it has delivered a complete, certified backside implementation flow to support Samsung Foundry’s SF2 process node.
  • This latest collaboration between Cadence and Samsung Foundry enables customers to leverage the Cadence® digital full flow and corresponding process design kit (PDK) to speed next-generation mobile, automotive, AI and hyperscale chip design innovation.
  • The complete Cadence RTL-to-GDS flow that is optimized for the Samsung Foundry 2nm process technology includes the Genus™ Synthesis Solution, Innovus™ Implementation System, Integrity™ 3D-IC platform, Quantus™ Extraction Solution, Pegasus™ Verification System, Voltus™ IC Power Integrity Solution, Tempus™ Timing Signoff Solution and Tempus ECO Option.
  • “The successful rollout of this backside design flow, fully supported by the Cadence digital flow, lets customers reap the benefits of our advanced SF2 technology.”
    “Designers can speed time to market by leveraging our collaboration with Samsung Foundry on the complete RTL-to-GDS flow and SF2 technology,” said Vivek Mishra, corporate vice president in the Digital & Signoff Group at Cadence.

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics

Retrieved on: 
Monday, June 26, 2023
Time trial, Therapy, CCI, ESR1, Clinical trial, Cancer, Fulvestrant, Mutation, JCO Clinical Cancer Informatics, Research, JCO, Trial of the century, Eli Lilly, Tempus, Patient, IRB, Oncology, TIME, Breast cancer, Pharmaceutical industry, Nursing

The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.

Key Points: 
  • The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.
  • Sermonix was able to leverage Tempus’ network of individual clinical sites that use a pre-approved clinical trial agreement and regulatory process, as well as a central IRB.
  • The duration for full clinical trial agreement execution averaged 200.5 days for traditional sites, compared to 7.6 days for TIME Trial sites.
  • These results demonstrate the value of employing both models for biomarker-driven studies.”
    Tempus is an industry leader analyzing multimodal data to identify actionable clinical trial options for cancer patients.